TLCR Annual Report (2015)

Greetings from Editorial Office of TLCR.

It’s our pleasure to present the 2015 Annual Report of TLCR here. With the join-efforts from experts worldwide, we are glad to see TLCR progressed fast and soundly in 2015. Details are shown in the Annual Report.

We extend our heartfelt gratitude to all our editorial board members, reviewers, authors and readers. Wish you a happy, healthy and prosperous 2016!

To see the full report at: https://tlcr.amegroups.org/article/view/5548/5478

To see the full report at:https://tlcr.amegroups.org/announcement/view/90

Article Title	Corresponding Authors
Advances on EGFR mutation for lung cancer	Lucio Crinò
Angiogenesis in cancer: Anti-VEGF escape mechanisms	Gerald W Prager
Irreversible EGFR-TKIs: dreaming perfection	Federico Cappuzzo
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?	Lothar R Pilz
MET inhibitors in combination with other therapies in non-small cell lung cancer	Heather Wakelee
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements	Rafael Rosell
ALK and ROS1 as a joint target for the treatment of lung cancer: a review	José I. Borrell
Adaptive resistance to targeted therapies in cancer	Rafael Rosell

Note: Data collected from Web of Knowledge^TMcore collection

All issues could be searched here:https://tlcr.amegroups.org/issue/archive

Announcements